

Haemochromatosis: Red Cross Blood Service policy

Margaret L Buring

Leader, Medical Services for Donor Related Issues, Australian Red Cross Blood Service Queensland, PO Box 10325, Adelaide Street, Brisbane, QLD 4000. mburing@bigpond.net.au

TO THE EDITOR: The Australian Red Cross Blood Service (ARCBS) introduced a national policy for therapeutic venesection in December 1999 which allows the collection of blood from people with haemochromatosis. There is no charge for this service.

The policy outlines the principles under which ARCBS provides a therapeutic venesection service, conditions of management of the donors and the acceptability of the donations for clinical use.¹ These conditions are:

- The patient's condition benefits from regular venesection and the patient does not have a transfusion-transmissible disease.
- The blood donation will be used in clinical or derivative products only if the donors fully meet the donor selection guidelines for clinical use.
- Responsibility for patient management remains with the referring physician.
- ARCBS is responsible for the collection and for ensuring donor safety during the procedure. We will liaise with referring physicians about the venesection protocol if necessary, and reserve the right to refuse to venesect if there is a concern for donor safety.

A diagnosis of hereditary haemochromatosis (evidence of iron overload together with appropriate genetic studies²) is required before patients are accepted into the therapeutic venesection program.

Contact your local ARCBS for copies of the therapeutic request form. Completion of this will facilitate the entry of people to the ARCBS therapeutic program.

The full policy can be obtained from our website <www.arcbs.redcross.org.au>.

1. Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices and risk assessment of blood donors with hemochromatosis. *JAMA* 2001; 286: 1475-1481.
2. Vautier G, Murray M, Olyk JK. Hereditary haemochromatosis: detection and management. *Med J Aust* 2001; 175: 418-421. □

An ecological perspective of cholesterol

Christopher H Cantor

Psychiatrist, PO Box 1216, Noosa Heads, QLD 4567. cantor98@powerup.com.au

TO THE EDITOR: The *Lipid management guidelines* — 2001 supplement¹ is no doubt full of cardiovascular wisdom. Unfortu-

nately, the authors appear oblivious to the fact that people are more than just cardiovascular systems. I found no mention of the risks of violent deaths associated with low cholesterol levels, which in some studies have been found to offset the decreased cardiovascular mortality benefits.²

In 1995, Engstrom et al neatly reviewed the relevant issues for those interested in populations of whole people.¹ They cite studies which found low cholesterol levels to be associated with homicidal offenders with habitual violent tendencies when under the influence of alcohol, boys with aggressive conduct disorder, and criminals with anti-social personality, as well as with increased depressive symptoms in men aged 50-89 years. Further, an evaluation of six primary prevention trials found a significant increase in violent deaths in groups receiving interventions to reduce serum cholesterol levels.²

Engstrom et al also reviewed studies which found increased aggression in cynomolgus monkeys fed a low-fat diet.¹ This appeared related to reduced serotonin activity, as serotonin is widely known to reduce aggression. In fairness, Engstrom and colleagues also cited studies which have not found an association between low cholesterol levels and aggression.¹

If the increase in violent deaths associated with changing the dietary habits of whole populations turns out to be more than a red herring, the ethical and financial implications will be staggering. This evidence is not so conclusive as to have made me change my own relatively low-fat diet, but they do make me wonder if my irritation about the oversight in the *Lipid management guidelines* — 2001¹ might have something to do with my low fat intake!

1. Lipid management guidelines — 2001. *MJA* 2001; 175 (Suppl 5 November): S57-S88.
2. Muldoon MF, Mannuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. *BMJ* 1990; 301: 309-314.
3. Engstrom G, Alsen M, Regnell G, Traskman-Bendz L. Serum lipids in suicide attempters. *Suicide Life-Threat Behav* 1995; 25: 393-400. □

MJA ADVERTISERS' INDEX

Medacs

Medical Recruitment p563

Roche Products

Dilatrend p510

Dilatrend prescribing information p534

Dilatrend "H.Krum" p520

Schering Pty Limited

Mirena Inside front cover

Diane 35-ED Inside back cover

Diane 35-ED prescribing information p562

Microgynon 20 Outside back cover

The Medical Journal of Australia

Editor

Martin Van Der Weyden, MD, FRACP, FRCPA

Deputy Editors

Bronwyn Gaut, MB_BS, DCH, DA

Ruth Armstrong, BMed

Mabel Chew, MB_BS(Hons), FRACGP, FACHPM

Kincaid-Smith Editorial Fellow

Jenny Bergen, MB_BS, FRANZCP

Manager, Communications Development

Craig Bingham, BA(Hons), DipEd

Senior Assistant Editor

Helen Randall, BSc, DipOT

Assistant Editors

Elsina Meyer, BSc

Kerrie Lawson, BSc(Hons), PhD, MASM

Tim Badgery-Parker, BSc(Hons)

Josephine Wall, BA, BAppSci, GradDipLib

Proof Reader

Richard Bellamy

Editorial Administrator

Kerrie Harding

Editorial Assistant

Christine Tsim

Production Manager

Glenn Carter

Editorial Production Assistant

Melissa Sherman

Librarian and Book Review Editor

Joanne Elliot, BA, GradDipLib

Consultant Biostatistician

Val GebSKI, BA, MStat

Content Review Committee

Mark Harris, MD, FRACGP

Adrian Mindel, MD, FRCP, FRACP

Michael Solomon, MB BCh(Hons), MSc, FRACS

John Wilson, MB BS, PhD, FRACP

Jeffrey Zajac, MB BS, PhD, FRACP

Editor Emeritus

Ronald R Winton, OAM, MB BS, FRACP

Australasian Medical Publishing Co Pty Ltd

Advertising & Business Development Manager

Peter Butterfield

Media Coordinator

Stephanie Elliott

The Medical Journal of Australia (MJA) is published on the 1st and 3rd Monday of each month by the Australasian Medical Publishing Company Proprietary Limited, Level 2, 26-32 Pyrmont Bridge Rd, Pyrmont, NSW 2009. ABN 20 000 005 854. Telephone: (02) 9562 6666. Fax: (02) 9562 6699. E-mail: ampco@ampco.com.au. The Journal is printed by Offset Alpine Printing Ltd, 42 Boorea St, Lidcombe, NSW 2141.

MJA on the Internet: <http://www.mja.com.au/>

None of the Australasian Medical Publishing Company Proprietary Limited, ABN 20 000 005 854, the Australian Medical Association Limited, or any of its servants and agents will have any liability in any way arising from information or advice that is contained in *The Medical Journal of Australia (MJA)*. The statements or opinions that are expressed in the Journal reflect the views of the authors and do not represent the official policy of the Australian Medical Association unless this is so stated. Although all accepted advertising material is expected to conform to ethical and legal standards, such acceptance does not imply endorsement by the Journal. All literary matter in the Journal is covered by copyright, and must not be reproduced, stored in a retrieval system, or transmitted in any form by electronic or mechanical means, photocopying, or recording, without written permission.

Published in 2 volumes per year.

Annual Subscription Rates for 2002 (Payable in Advance) to: AMPCo, Locked Bag 3030, Strawberry Hills, NSW 2012

Individual Subscriptions (includes 10% GST)

Australia—\$A284.90, Medical students (Australia only)—\$A55.00

Overseas Economy Air—\$A396.00, Airmail—\$A539.00

NZ & PNG Economy Air—\$A363.00, Airmail—\$A490.00

Indexes are published every 6 months and are available on request as part of the current subscription.

Single or back issues contact: AMPCo (02) 9562 6666.

Advice to Authors—<http://www.mja.com.au/public/information/instruct.html>



27,324 circulation as at 31 March, 2002



ISSN 0025-729X